OncoMatch/Clinical Trials/NCT06738303
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
Is NCT06738303 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cabazitaxel and carboplatin and Lu-PSMA-617 for metastatic prostate cancer.
Treatment: Cabazitaxel and carboplatin · Lu-PSMA-617 — The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA) positive.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Biomarker criteria
Allowed: TP53 mutation
two of the following: TP53, PTEN, RB1 mutation
Allowed: PTEN mutation
two of the following: TP53, PTEN, RB1 mutation
Allowed: RB1 mutation
two of the following: TP53, PTEN, RB1 mutation
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: androgen receptor pathway inhibitor
Lab requirements
Blood counts
Absolute neutrophil count >1000/μL; platelet count >90,000/μL; hemoglobin >8.5 g/dL; no growth factors within 7 days or blood transfusions within 14 days prior to labs
Kidney function
Creatinine clearance ≥40 mL/min and/or eGFR ≥30
Liver function
Total bilirubin <2.5 × ULN (except Gilbert syndrome <3 mg/dL); ALT and AST <5 ULN
Subjects must have adequate organ and marrow function as defined below to be suitable for the randomized treatment outlined in this: * Absolute neutrophil count >1000/μL; platelet count >90 000/μL; hemoglobin >8.5 g/dL) at screening. Note: Subjects must not have received any growth factors within 7 days or blood transfusions within 14 days prior to the hematologic laboratory values obtained at screening). * Total bilirubin (TBIL) <2.5 × the upper limit of normal (ULN) at screening, except subjects with documented Gilbert syndrome who must have a TBIL <3 mg/dL * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5 ULN at screening * Creatinine clearance ≥40 mL/min and/or estimated glomerular filtration rate (eGFR) ≥30 * Albumin >30 g/L (3.0 g/dL) at screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Center · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify